USPTO Examiner FAUST AMBER KATHLEEN - Art Unit 1643

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18919069ANTIGEN BINDING POLYPEPTIDESOctober 2024January 2025Allow300YesNo
18887598ANTIBODIES SPECIFICALLY BINDING TO CD147 AND USES THEREOFSeptember 2024March 2025Allow610YesNo
18307299ANTIBODIES BINDING BCMA AND CD3 AND USES THEREOFApril 2023May 2024Allow1211NoNo
18119103PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF CANCERMarch 2023October 2024Abandon2010NoNo
18154597TM4SF5-TARGETING HUMANIZED ANTIBODY AND USE THEREOFJanuary 2023June 2024Allow1711YesNo
18089393BINDING MOLECULE ABLE TO NEUTRALIZE PROX1 PROTEINDecember 2022May 2024Allow1711YesNo
17592105FORMULATIONS AND PROCESSES FOR CAR T CELL DRUG PRODUCTSFebruary 2022January 2025Allow3520NoYes
17490582MODIFIED CELL AND USE THEREOF IN GENE AND CELL THERAPYSeptember 2021November 2023Allow2500YesNo
17598737Efflux Pump-Cancer Antigen Multi-Specific Antibodies and Compositions, Reagents, Kits and Methods Related TheretoSeptember 2021February 2025Allow4110NoNo
17442939ANTI-CLAUDIN 18.2 ANTIBODY AND APPLICATION THEREOFSeptember 2021May 2025Allow4410NoNo
17436951THREONINE166 AND SERINE189 OF RUBICON RUN DOMAIN AS LRRK2 KINASE INHIBITION TARGET SITESSeptember 2021February 2025Allow4110NoNo
17435387LILRB4-BINDING ANTIBODY AND METHODS OF USE THEREOFAugust 2021August 2024Allow3600YesNo
17430144BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO IL-17A AND TNF-AlphaAugust 2021September 2024Allow3701YesNo
17429584MODULATION OF WNT SIGNALLING IN OCULAR DISORDERSAugust 2021March 2025Allow4310YesNo
17429208ANTI-ANG2 ANTIBODY AND USE THEREOFAugust 2021January 2025Abandon4101NoNo
17395996DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCERAugust 2021July 2024Allow3500YesNo
17428816ANTIBODIES AGAINST hEPCRAugust 2021October 2024Allow3801YesNo
17428079TREATMENT OF CUTANEOUS T CELL LYMPHOMA WITH TARGETING OF CD47 PATHWAYAugust 2021April 2025Abandon4410NoNo
17380251Therapeutic RNA and Anti-PD1 Antibodies for Advanced Stage Solid Tumor CancersJuly 2021January 2025Abandon4201NoNo
17423344Method for Counting Cell Types or Cell Markers In a Sample, In Particular In a Blood SampleJuly 2021January 2025Allow4210NoNo
17353617Humanized Anti-PD-1 Antibody and The Use ThereofJune 2021June 2024Allow3500YesNo
17055799COMPLEX HAVING ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT, PEPTIDE LINKER AND/OR LIGANDJune 2021November 2024Allow4820NoNo
17312523METHODS AND COMPOSITIONS RELATING TO IMPROVED FORMS OF TARGETED ERYTHROPOIETINJune 2021December 2024Abandon4201NoNo
17342513T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use ThereofJune 2021May 2025Abandon4711NoNo
17311258Humanized and Affinity-Matured Anti-CEACAM1 AntibodiesJune 2021August 2024Allow3810YesNo
17299086ANTI-C-MET AGONIST ANTIBODY AND USE THEREOFJune 2021August 2024Allow3810NoNo
17299274LONG-ACTING EXENDIN-4 AND USE THEREOFJune 2021August 2024Allow3910YesNo
17291701CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIESMay 2021September 2024Allow4010YesNo
17291198ANTI-LIV1 IMMUNE CELL CANCER THERAPYMay 2021February 2025Abandon4501NoNo
17290480ANTI-TNFALPHA/ANTI IL - 17A NATURAL ANTIBODY STRUCTURE-LIKE HETERODIMER FORM OF BISPECIFIC ANTIBODY AND PREPARATION METHOD THEREFORApril 2021February 2025Allow4521NoNo
17287462Anti-B7-H4 Chimeric Antigen Receptor-Modified NK-92 CellsApril 2021August 2024Allow4010YesNo
17284946Targeting the Non-Canonical NFkB Pathway in Cancer ImmunotherapyApril 2021October 2024Abandon4210NoNo
17284948METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCERApril 2021June 2025Abandon5021NoNo
17229856COMBINATION INCLUDING A CPG-C TYPE OLIGONUCLEOTIDE AND A PD-1 ANTAGONIST FOR TREATING BREAST CANCERApril 2021October 2024Abandon4310NoNo
17284672NOVEL ANTI-C-KIT ANTIBODYApril 2021August 2024Allow4010YesNo
17283434ANTIBODIES AND THERAPEUTIC USES THEREOFApril 2021August 2024Allow4000YesNo
17281372COMBINATION THERAPY OF CLDN18 ANTIBODY AND CHEMOTHERAPY DRUGSMarch 2021September 2024Abandon4101NoNo
17281058PDGF RECEPTOR ANTIBODY AND USE THEREOFMarch 2021May 2024Allow3801YesNo
17280766CSF1R/CCR2 MULTISPECIFIC ANTIBODIESMarch 2021March 2025Abandon4821YesNo
17276553ANTI-LMP2 TCR-T CELL THERAPY FOR THE TREATMENT OF EBV-ASSOCIATED CANCERSMarch 2021July 2024Allow4010NoNo
17275140METHODS OF MODULATING ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITYMarch 2021March 2025Abandon4920NoNo
17273172SPECIFIC MONOCLONAL ANTIBODY AGAINST THE N ANTIGEN OF HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) USEFUL FOR TREATING INFECTION, DETECTION THEREOF AND DIAGNOSISMarch 2021April 2024Allow3710YesNo
17273082METHODS AND COMPOSITIONS FOR TREATING ASTHMA AND ALLERGIC DISEASESMarch 2021November 2024Allow4421YesNo
17270571CHIMERIC ANTIGEN RECEPTOR CELLS FOR TREATING SOLID TUMORFebruary 2021July 2024Allow4110YesNo
17269991METHODS OF TREATING NEURODEGENERATIVE DISEASESFebruary 2021June 2024Allow4010YesNo
17269456ANTI-TIM3 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOFFebruary 2021October 2024Abandon4301NoNo
17265016MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING POMPE DISEASEFebruary 2021January 2024Abandon3601NoNo
17261998METHODS FOR TARGETING, INHIBITING, AND TREATING A TUMORAL MICROENVIRONMENTJanuary 2021May 2025Abandon5230NoNo
17260974ANTI-PD-1 ANTIBODIES, DOSAGES AND USES THEREOFJanuary 2021December 2024Allow4720YesNo
17251196PANCREATIC CANCER DETERMINATION MARKERDecember 2020February 2025Abandon5011NoNo
17048549ANTI-ROR ANTIBODY CONSTRUCTSOctober 2020May 2024Allow4301YesNo
16963047COMPOSITIONS AND METHODS FOR TARGETING GAMMA DELTA T CELLS WITH CHIMERIC ANTIGEN RECEPTORSJuly 2020September 2024Allow5011YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FAUST, AMBER KATHLEEN.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
1
(100.0%)
Filing Benefit Percentile
0.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner FAUST, AMBER KATHLEEN - Prosecution Strategy Guide

Executive Summary

Examiner FAUST, AMBER KATHLEEN works in Art Unit 1643 and has examined 50 patent applications in our dataset. With an allowance rate of 66.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner FAUST, AMBER KATHLEEN's allowance rate of 66.0% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by FAUST, AMBER KATHLEEN receive 0.88 office actions before reaching final disposition. This places the examiner in the 9% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by FAUST, AMBER KATHLEEN is 41 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +57.4% benefit to allowance rate for applications examined by FAUST, AMBER KATHLEEN. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 41.7% of applications are subsequently allowed. This success rate is in the 92% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 99% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.